Biodexa Pharmaceuticals Plc (5MP0.SG)

0,8500 0,0000 (0,00%) Ab 08:18AM CEST. Markt geöffnet.

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff CF10 4DQ
United Kingdom
44 29 2048 0180
https://www.biodexapharma.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 21

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stephen A. Stamp	CEO, CFO, Company Secretary & Director	294,92k	N/A	1962
Dr. Dmitry Zamoryakhin M.D.	Chief Scientific Officer & Chief Medical Officer	278,95k	N/A	1980
Dr. Daniel Palmer MBA, Ph.D.	Vice President of Technology	N/A	N/A	N/A
Ms. Nicola Tuckwell	VP & Head of Clinical Operations	N/A	N/A	N/A
Steve Ellul	Chief Business Officer	N/A	N/A	N/A
Ms. Fiona Sharp	Group Financial Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Corporate Governance

Biodexa Pharmaceuticals Plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.